全文获取类型
收费全文 | 25002篇 |
免费 | 2797篇 |
国内免费 | 104篇 |
专业分类
耳鼻咽喉 | 205篇 |
儿科学 | 1006篇 |
妇产科学 | 686篇 |
基础医学 | 3560篇 |
口腔科学 | 439篇 |
临床医学 | 3687篇 |
内科学 | 5264篇 |
皮肤病学 | 591篇 |
神经病学 | 2595篇 |
特种医学 | 600篇 |
外国民族医学 | 4篇 |
外科学 | 2615篇 |
综合类 | 215篇 |
一般理论 | 5篇 |
预防医学 | 2472篇 |
眼科学 | 309篇 |
药学 | 1700篇 |
中国医学 | 20篇 |
肿瘤学 | 1930篇 |
出版年
2023年 | 251篇 |
2022年 | 153篇 |
2021年 | 712篇 |
2020年 | 647篇 |
2019年 | 972篇 |
2018年 | 1106篇 |
2017年 | 883篇 |
2016年 | 909篇 |
2015年 | 957篇 |
2014年 | 1169篇 |
2013年 | 1671篇 |
2012年 | 1982篇 |
2011年 | 1896篇 |
2010年 | 1230篇 |
2009年 | 1060篇 |
2008年 | 1538篇 |
2007年 | 1500篇 |
2006年 | 1394篇 |
2005年 | 1309篇 |
2004年 | 1220篇 |
2003年 | 1087篇 |
2002年 | 1002篇 |
2001年 | 218篇 |
2000年 | 194篇 |
1999年 | 203篇 |
1998年 | 226篇 |
1997年 | 183篇 |
1996年 | 133篇 |
1995年 | 169篇 |
1994年 | 148篇 |
1993年 | 118篇 |
1992年 | 110篇 |
1991年 | 108篇 |
1990年 | 100篇 |
1989年 | 88篇 |
1988年 | 85篇 |
1987年 | 61篇 |
1986年 | 70篇 |
1985年 | 67篇 |
1984年 | 81篇 |
1983年 | 75篇 |
1982年 | 88篇 |
1981年 | 88篇 |
1980年 | 63篇 |
1979年 | 37篇 |
1978年 | 41篇 |
1977年 | 45篇 |
1976年 | 62篇 |
1975年 | 44篇 |
1974年 | 47篇 |
排序方式: 共有10000条查询结果,搜索用时 250 毫秒
61.
62.
63.
64.
Johana Béné Aurélie Jacobsoone Patrick Coupe Marine Auffret Samy Babai Dominique Hillaire‐Buys Marie‐Josèphe Jean‐Pastor Marlène Vonarx Annie Vermersch Anne‐Fleur Tronquoy Sophie Gautier 《Fundamental & clinical pharmacology》2015,29(1):112-114
To report three cases of bullous pemphigoid in patients treated with vildagliptin. Case 1: An 86‐year‐old woman presented with bullous pemphigoid after 1 month of treatment with vildagliptin and metformin. After introduction of clobetasol, the symptoms resolved although vildagliptin was continued. However, the skin lesions reappeared 3 months later. Sustained remission was achieved only after definitive withdrawal of vildagliptin. Case 2: A 79‐year‐old man presented with bullous pemphigoid after 37‐month treatment with gliclazide, vildagliptin and metformin. The disease at first responded to clobetasol but 3 months later the lesions reappeared. They finally regressed when the gliptin was discontinued. Case 3: A 77‐year‐old woman, treated with gliclazide and vildagliptin for 26 months, presented with bullous pemphigoid, which responded well to discontinuation of the gliptin and topical clobetasol. Gliptins are new molecules for treatment of type 2 diabetes mellitus, which have been suspected of implication in bullous pemphigoid. Such cases have been described in the literature (seven with vildagliptin and three with sitagliptin). In nine of these cases, the gliptin was associated with metformin, but the latter had never been considered responsible. The mechanism implicated in the development of bullous pemphigoid has not yet been clearly identified, but may involve a modified immune response or alteration of the antigenic properties of the epidermal basement membrane. These reports support the risk of bullous pemphigoid in patients exposed to gliptins. 相似文献
65.
Effects of acute administration of melatonin on attentional,executive, and working memory processes in rats 下载免费PDF全文
Christophe Liet Fella Amenouche Thomas Freret Michel Boulouard Benoit Mauvieux Véronique Lelong‐Boulouard Marie‐Laure Bocca 《Fundamental & clinical pharmacology》2015,29(5):472-477
Melatonin is a potential candidate for additive therapy in cancer, neurodegenerative, and mental disorders requiring administration during the activity phase. Nevertheless, because melatonin has mostly been used as a hypnotic, less is known about its cognitive effects. In this study, we investigated the effects of acute administration of melatonin on executive, attentional, and working memory processes in rats during the activity phase. Three doses of melatonin (6, 18, or 36 mg/kg) were tested and compared to a saline control group in two behavioral tests: the Attentional Set Shifting task (for attentional and executive processes assessment) and the Spontaneous Alternation test in a Y‐maze (for working memory assessment). Our results revealed that, up to 36 mg/kg, the acute administration dose of melatonin did not alter the attentional or executive processes, nor the working memory in rats. Consequently, this result may be encouraging for the use of melatonin in additive therapy during the activity phase. 相似文献
66.
Fiene Marie Kuijper Uma V. Mahajan Seul Ku Daniel A.N. Barbosa Sheila M. Alessi Sherman C. Stein Kyle M. Kampman Brandon S. Bentzley Casey H. Halpern 《Neuromodulation》2022,25(2):253-262
ObjectivesCocaine is the second most frequently used illicit drug worldwide (after cannabis), and cocaine use disorder (CUD)-related deaths increased globally by 80% from 1990 to 2013. There is yet to be a regulatory-approved treatment. Emerging preclinical evidence indicates that deep brain stimulation (DBS) of the nucleus accumbens may be a therapeutic option. Prior to expanding the costly investigation of DBS for treatment of CUD, it is important to ensure societal cost-effectiveness.AimsWe conducted a threshold and cost-effectiveness analysis to determine the success rate at which DBS would be equivalent to contingency management (CM), recently identified as the most efficacious therapy for treatments of CUDs.Materials and MethodsQuality of life, efficacy, and safety parameters for CM were obtained from previous literature. Costs were calculated from a societal perspective. Our model predicted the utility benefit based on quality-adjusted life-years (QALYs) and incremental-cost-effectiveness ratio resulting from two treatments on a one-, two-, and five-year timeline.ResultsOn a one-year timeline, DBS would need to impart a success rate (ie, cocaine free) of 70% for it to yield the same utility benefit (0.492 QALYs per year) as CM. At no success rate would DBS be more cost-effective (incremental-cost-effectiveness ratio <$50,000) than CM during the first year. Nevertheless, as DBS costs are front loaded, DBS would need to achieve success rates of 74% and 51% for its cost-effectiveness to exceed that of CM over a two- and five-year period, respectively.ConclusionsWe find DBS would not be cost-effective in the short term (one year) but may be cost-effective in longer timelines. Since DBS holds promise to potentially be a cost-effective treatment for CUDs, future randomized controlled trials should be performed to assess its efficacy. 相似文献
67.
68.
Norah Anthony Delphine Bourneau-martin Sarah Ghamrawi Laurence Lagarce Marina Babin Marie Briet 《Fundamental & clinical pharmacology》2020,34(6):736-742
Vitiligo is a common depigmenting disorder ensuing the loss of epidermal melanocytes. It is a multifactorial disease with immunological, genetic and environmental factors including drug exposure. The purpose of the study was to investigate the drugs and therapeutic subclasses associated with vitiligo occurrence reported in VigiBase®, the WHO pharmacovigilance database. A case/non-case study was carried out by defining cases as vitiligo reports and non-cases as all other reports. The reporting odds ratio (ROR) was calculated for the ‘suspected’ drugs and drug classes according to ATC level 4. During the study period, 741 cases of vitiligo were registered. Mean age was 49 ± 20 years. The disproportionality analysis showed an association between vitiligo and pembrolizumab (ROR 116.9, 95% Confidence Interval (CI) 94.8, 144.3), nivolumab (ROR 22.6, 95% CI 15.8, 32.4), ipilimumab (ROR 41.7, 95% CI 25.0, 69.7), imiquimod (ROR 152.8, 95% CI 103.0, 226.7), adalimumab (ROR 3.8, 95% CI 2.5,5.8), infliximab (ROR 2.6, 95% CI 1.65, 4.01), alemtuzumab (ROR 27.8, 95% CI 17.6, 43.9), and ustekinumab (ROR 9.3, 95% CI 5.6, 15.6). Concerning the pharmacological classes ATC level 4, a significant association was found with monoclonal antibodies, interferons, selective immunosuppressants, TNF-alpha inhibitors, interleukin inhibitors, and topical antivirals. This study confirmed the expected associations between vitiligo and immune checkpoint inhibitors and strengthened the emerging signal about the association between vitiligo and imiquimod, TNF-alpha inhibitors and interferons. New signals were shown with selective immunosuppressants including alemtuzumab and interleukin inhibitors. 相似文献
69.
70.